Ipamorelin: The Selective Growth Hormone Secretagogue

The short version

Ipamorelin is a synthetic five-amino-acid peptide that acts on a receptor in the pituitary gland called GHS-R1a — the same receptor that the hunger hormone ghrelin activates — to trigger a pulse of growth hormone (GH) release. What made it notable when it was first characterized in 1998 was selectivity: unlike earlier growth-hormone-releasing peptides, it produced potent GH release without meaningfully raising cortisol, ACTH or prolactin, even at doses more than 200-fold above its effective concentration ^[11].

Ipamorelin has never been approved as a drug anywhere. Its one published controlled human trial, testing it for postoperative ileus in bowel-resection patients, did not meet its primary endpoint ^[8]. Human pharmacokinetic data do exist — from a 1999 study in healthy male volunteers — showing a terminal half-life of roughly two hours and a peak GH response around 40 minutes post-dose ^[9]. Long-term human safety data do not exist.

Popular clinic promotion of ipamorelin for anti-aging, fat loss and muscle gain rests largely on mechanism and short animal studies, not on controlled human outcome trials. This page summarizes what was actually studied.

What it is

Ipamorelin is a synthetic pentapeptide with the sequence Aib-His-D-2-Nal-D-Phe-Lys-NH2 — the unusual building blocks (alpha-aminoisobutyric acid, D-2-naphthylalanine, D-phenylalanine) confer resistance to breakdown by protease enzymes, which is part of why it survives longer in the body than natural peptides with similar sequences. It was developed as a derivative of GHRP-1 and is catalogued in the research literature under the designations NNC 26-0161 and NNC-26-0161.

Its class is the growth hormone secretagogues (GHSs) — synthetic compounds that mimic or amplify ghrelin's action at the GHS-R1a receptor. The GHS class includes compounds like GHRP-6 and GHRP-2, but ipamorelin's defining feature is that it does the GH-releasing work without the off-target hormonal effects those earlier compounds carried ^[11]. It is distinct from the compound sometimes combined with it (CJC-1295, a GHRH analog that works by an entirely different mechanism); the two are separate research peptides.

How it works: the GHS-R1a secretagogue mechanism

When ipamorelin binds GHS-R1a receptors on pituitary somatotrophs — the cells that produce growth hormone — it triggers a discrete pulse of GH release. This is the normal physiology of GH secretion: the pituitary releases GH in pulses, and ipamorelin amplifies or initiates those pulses by mimicking ghrelin at the receptor level ^[11].

The selectivity picture, from the 1998 founding characterization in rat pituitary cells, anesthetized rats and conscious swine, is clear: at doses far exceeding the GH effective dose, ipamorelin did not raise ACTH or cortisol above levels seen with the growth hormone-releasing hormone itself ^[11]. This makes it distinct from GHRP-6 and GHRP-2, which do raise those stress hormones. Ipamorelin's founding paper called it "the first selective growth hormone secretagogue" ^[11].

Beyond the pituitary, GHS-R1a receptors are expressed in the gut (explaining effects on gastric motility), in pancreatic islet cells (where preclinical data show direct insulin-releasing effects independent of GH), and in hypothalamic appetite circuits where ghrelin agonism drives feeding behavior. These additional sites mean ipamorelin's pharmacology is not limited to the GH axis — a fact relevant to understanding both its potential effects and its cautions ^[9].

What the research shows

Founding selectivity characterization (1998, rodents and swine). Ipamorelin produced potent GH release — comparable to GHRP-6 — in rat pituitary cells, anesthetized rats and conscious swine, with a swine ED50 of 2.3 nmol/kg versus 3.9 nmol/kg for the older compound, and no significant ACTH or cortisol elevation at doses more than 200-fold above the GH ED50 ^[11]. This defined the compound and its class advantage.

Bone growth (1999, rats). Subcutaneous ipamorelin at three dose levels given three times daily for 15 days dose-dependently increased longitudinal bone growth rate in adult female rats, from 42 microns/day with vehicle to 52 microns/day at the highest dose studied, without measurable change in total IGF-1 or bone turnover markers ^[10]. This suggests a partly local or GH-pulse-driven effect on bone rather than one purely mediated by systemic IGF-1.

Human pharmacokinetics (1999). In healthy male volunteers (n=8 per dose level) given five 15-minute IV infusions of varying amounts, ipamorelin showed dose-proportional kinetics with a terminal half-life of approximately 2 hours, clearance of 0.078 L/h/kg, and a GH response peaking roughly 40 minutes after dosing as a single discrete pulse ^[9]. This is one of the few published human ipamorelin datasets.

Phase 2 human trial (2014) — failed primary endpoint. In 114 adults undergoing bowel resection (NCT00672074), IV ipamorelin twice daily for up to 7 days did not significantly reduce the median time to first tolerated meal (25.3 hours ipamorelin versus 32.6 hours placebo; p=0.15). Treatment-emergent adverse events occurred in 87.5% of the ipamorelin arm and 94.8% of the placebo arm, with no ipamorelin-specific safety signal in this short perioperative window ^[8]. This is the defining human efficacy anchor: the drug failed its clinical test.

Chemotherapy-associated weight loss (2024, ferrets). Ipamorelin at 1-3 mg/kg reduced cisplatin-induced body-weight loss by approximately 24% on the last day of the delayed phase in a ferret model, but had no anti-emetic effect — a peripheral mechanism distinct from the central anti-nausea action of a related compound ^[6].

Class-level cardiovascular signal (2015, rats). A 28-day safety study of a related GHS-R1a agonist (not ipamorelin itself) found dose-dependent myocardial degeneration and necrosis in rats, detectable by histopathology and elevated cardiac fatty-acid-binding protein ^[7]. Ipamorelin itself has not been tested in an equivalent long-duration cardiovascular safety study; this is a class-level caution, not a finding about ipamorelin specifically.

Sports medicine narrative review (2026). A USC Keck School of Medicine review found that a CJC-1295 plus ipamorelin combination improved maximal muscle tension in a murine glucocorticoid-induced muscle-loss model, but concluded that safety and dosing data remain unknown for ipamorelin and that significant research is required before clinical recommendations can be made ^[12].

Reported effects, cautions and safety

Anecdotal community reports (anecdotal, not clinical evidence): The most consistently cited benefit in research-use community accounts is deeper, more restorative sleep, with users describing falling asleep faster and waking more rested — typically reported within one to two weeks of a pre-bed protocol. Vivid dreams in the early weeks are frequently mentioned, often described as transient. Faster post-training recovery and reduced muscle soreness appear commonly. Gradual shifts toward leaner body composition are occasionally reported from weeks five to twelve, though these are confounded by concurrent diet and training changes.

The most common adverse report is facial flushing and a head-rush feeling 5-15 minutes after injection, lasting up to an hour; this is widely discussed in community threads. Tingling or mild numbness in hands and feet, mild water retention, increased hunger in the hours after injection, and injection-site redness are also occasionally reported. Some users note transient lightheadedness shortly after injecting. A diminishing response after three to four months of continuous use is reported by some.

Literature-grounded cautions:

• Ipamorelin has never been approved as a drug; its Phase 2 trial failed its primary endpoint ^[8].
• The only controlled human safety window is 7 days IV; no long-term human safety data exist ^[8][9].
• GH stimulation raises theoretical concerns about IGF-1 and tumor promotion in those with active or occult malignancy — a class-level, mechanistic caution, not a documented ipamorelin-specific finding ^[11][10].
• GH is a counter-regulatory hormone; dual metabolic effects (GH-driven insulin resistance plus direct pancreatic islet cell signaling) create unpredictable glycemic impact in those with pre-existing insulin dysregulation.
• The class-level cardiovascular signal from a related compound (myocardial degeneration in rats) is relevant context for chronic use, though ipamorelin-specific long-term cardiac data do not exist ^[7].
• Ghrelin-receptor agonism can increase appetite and promote adiposity by a mechanism independent of GH, which matters for those where weight gain would be harmful.
• Ipamorelin is prohibited in sport at all times under WADA category S2 (Peptide Hormones and Growth Factors).
• Research-grade material from unregulated suppliers has no verified purity, identity or sterility.

Where it fits in Research Peptide Fundamentals

Ipamorelin is the featured lead of this desk because it sits at a fascinating pivot point in the growth hormone secretagogue story: it achieved what its predecessors could not (selectivity at GHS-R1a without cortisol/prolactin elevation), but then failed the one controlled human efficacy test it was put through ^[8][11]. Its pharmacology is elegant; its clinical career is a cautionary lesson in how selectivity at the receptor level does not automatically translate into clinical efficacy.

Compared with BPC-157, which repairs tissue by driving angiogenesis at the injury site, ipamorelin works further upstream — signaling the pituitary to release GH that then affects downstream tissues broadly. Compared with Retatrutide, which operates through metabolic-incretin signaling, ipamorelin's target system is the somatotropic axis rather than energy balance. Compared with Thymosin Alpha-1, which modulates immunity, ipamorelin has no established immune-directed mechanism. See the compare page for a structured side-by-side.